Tag Archives: Celgene

Hey, naysayers: Bristol-Myers’ Celgene buy just chalked up another point in its favor

Bristol-Myers Squibb scored more bragging rights for its coming megamerger: The FDA is now officially reviewing one of the “Big 5” Celgene candidates touted as cornerstones of the deal. And it’s ozanimod, the blockbuster MS prospect whose application the FDA wouldn’t even consider last year. Regulators in both the U.S. and Europe accepted Celgene’s ozanimod filings to… Read More »

Don’t worry about our $19B bond issue, BMS says. With Celgene, we’ll have the cash to pay it off

Bristol-Myers Squibb sold $ 19 billion in bonds on Tuesday, 2019’s largest bond issue so far. (BMS) Bristol-Myers Squibb is taking on a debt load to cover its $ 74 billion Celgene buyout, and it issued $ 19 billion in bonds Tuesday to help pay the bill. Bristol-Myers issued bonds in nine tranches that come due starting… Read More »

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal

It’s not only Celgene investors who are set for a big payoff with this week’s $ 74 billion sale to Bristol-Myers Squibb. Thanks to brand-new severance agreements inked days ahead of the deal announcement, its top executives could reap hefty gains, too. Under change-in-control severance arrangements that took effect Dec. 17, top Celgene managers would… Read More »